DOI: https://doi.org/10.18370/2309-4117.2020.53.94-100

Vaginal discharge syndrome. Problem with many unknowns

Т. Ф Татарчук, Л. В. Калугіна, Г. А. Петрова, В. В. Радченко, В. В. Шаверська, А. М. Сорокіна, О. В. Смирнова

Abstract


The main reason for visiting an obstetrician-gynecologist is the vaginal discharge syndrome (VDS) of infectious etiology. The most common causes of infectious vaginitis wich are identifed by European researchers are bacterial vaginosis (BV), aerobic vaginitis, vulvovaginal candidiasis and mixed infections. Treatment of VDS is a serious problem not only because of the pathogens’s resistance and frequent recurrences, but especially due to the COVID-19 pandemic which can complicate further patient`s examination for determination of infectious agent and the choice of individual approach to etiotropic therapy.

Purpose of study: to investigate the structure of causes of pathological vaginal discharge in Ukrainian women, as well as assess the compliance and effectiveness of their treatment.

Methods: 472 doctors of women's consultation centres, gynecological hospitals and centers of reproductive medicine from 23 regions of Ukraine were enrolled in multi-center study of vulvovaginal infections management. During the study, which lasted from August to December 2019, were examined 45,295 patients aged 18 to 59 years who complained for pathological vaginal discharge.

Results: analysis of the structure of nosologies that caused VDS showed that the examined patients were most often diagnosed with BV (41.1%), colpitis of mixed etiology (26.59%) and vulvovaginal candidiasis (19.22%), trichomoniasis was confirmed in 8.44%. The interviewed gynecologists preferred topical therapy in 95,99% cases of BV and colpitis of mixed etiology. Topical combined medications were prescribed in 85,21% of cases, monoforms – in 14.79%. Among the combined vaginal dosage forms the combination of metronidazole 750 mg /miconazole 200 mg was preferred in 48.81% of cases with clinical efficacy 87.1% in patients with BV and 86,9% in women with mixed infection. Normalization of the vaginal biocenosis was observed in 93.50% of the examined patients. The study demonstrated the safety, good tolerability and compliance of patients to therapy with the combined medications metronidazole 750 mg / miconazole 200 mg in vaginal suppositories.

Conclusion: BV, colpitis of mixed etiology and vulvovaginal candidiasis are predominated in structure of main causes of VDS in Ukraine. In the treatment of VDS, priority is given to vaginal forms with the most compliant (89.8%) regimen: once a day for a short period (7 days). The obtained high bacteriological (93.50%) and clinical (86,9%) efficacy of therapy of BV and vaginal mixed infections with the combined drug metronidazole 750 mg / miconazole 200 mg allows to recommend it as the drug of choice.


Keywords


vaginal discharge syndrome; bacterial vaginosis; mixed infection; treatment; metronidazole; miconazole

References


Sherrard, J., Wilson, J., Donders, G., et al. “European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge.” International Journal of STD & AIDS 29.13 (2018): 1258–72.

Kalugina, L.V., Tatarchuk, T.F., Shakalo, I.N., et al. “Nonspecific vulvovaginitis of mixed etiology: local treatment – the treatment of choice.” Reproductive endocrinology 1.27 (2016): 94–100. DOI: /10.18370/2309-4117.2016.27.94-100

Frobenius, W., Bogdan, C. “Diagnostic Value of Vaginal Discharge, Wet Mount and Vaginal pH – An Update on the Basics of Gynecologic Infectiology.” Geburtshilfe Frauenheilkd 75.4 (2015): 355–66.

Curry, A., Williams, T., Penny, M.L. “Pelvic Inflammatory Disease: Diagnosis, Management, and Prevention.” Am Fam Physician 100 (2019): 357–64.

Burka, O.A., Tutchenko, T.M., Pedachenko, N.Y. “Modern approaches to the choice of antimicrobial agents for pelvic inflammatory diseases: the role of innovative microbiological methods.” Reproductive endocrinology 1.51 (2020): 25–31. DOI: 10.18370/2309-4117.2020.51.25-31

Tai, F.-W., Chang, C., Chiang, J.-H., et al. “Association of Pelvic Inflammatory Disease with Risk ofEndometriosis: A Nationwide Cohort Study Involving 141,460 Individuals.” J Clin Med 7 (2018): 379. DOI: 10.3390/jcm7110379

Stewart, L.M., Stewart, C.J.R., Spilsbury, K., et al. “Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma.” Gynecol Oncol (2020). DOI:10.1016/j. ygyno.2020.01.027

Brotman, R.M., Klebanoff, M.A., Tonia, R., et al. “Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection.” J Infect Dis 202 (2010): 1907–15.

Rathod, S.D., Krupp, K., Klausner, J.D., et al. “Bacterial vaginosis and risk for Trichomonas vaginalis infection: a longitudinal analysis.” Sex Transm Dis 38 (2011): 882–6.

Haggerty, C.L., Totten, P.A., Tang, G., et al. “Identification of novel microbes associated with pelvic inflammatory disease and infertility.” Sex Transm Infect 92 (2016): 441–6.

Workowski, K.A., Bolan, G.A. “Sexually Transmitted Diseases Treatment Guidelines.” MMWR Recomm Rep 64 (RR 03) (2015): 1–137.

Kuznetsova, I.V. “Diagnosis and therapy of mixed and recurrent vulvovaginal infections.” Medical alphabet 25.3 (2019): 23–29.

Patterson, J.L., Girerd, P.H., Karjane, N.W., Jefferson, K.K. “Effect of biofilm phenotype on resistance of Gardnerella vaginalis to hydrogen peroxide and lactic acid.” Am J Obstet Gynecol 197 (2007): 170.

Gusak, Y.K., Rischuk, S.V., Tarasov, V.N., et al. “Infectious diseases of the vagina. Finding the best solution in their therapy. Defense or attack?” Bulletin of new medical technologies. Electronic resource 4 (2019): 22–40.

Mason, M.J., Winter, A.J. “How to diagnose and treatbaerobic and desquamative inflammatory vaginitis.” Sex Transm Infect 93 (2017): 8–10.

Brotman, R.M., Klebanoff, M.A., Nansel, T.R., et al. “A longitudinal study of vaginal douching and bacterial vaginosis – a marginal structural modeling analysis.” Am J Epidemiol 168 (2008): 188–96.

Bradshaw, C.S., Vodstrcil, L.A., Hocking, J.S., et al. “Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use.” Clin Infect Dis 56 (2013): 777–86.

Neut, C., Verrière, F., Nelis, H.J., Coenye, T. “Topical Treatment of Infectious Vaginitis: Effects of Antibiotic, Antifungal and Antiseptic Drugs on the Growth of Normal Vaginal Lactobacillus Strains.” Open Journal of Obstetrics and Gynecology 5 (2015): 173–180. DOI: 10.4236/ojog.2015.53024

McMillan, A., Dell, M., Zellar, M.P., et al. “Disruption of urogenital biofilms by lactobacilli.” Colloids Surf B Biointerfaces 86 (2011): 58–64. DOI: 10.1016/j. colsurfb.2011.03.016

Iungin, O.S. “Antifungal agents in the context of acquired resistance in fungi of the genus Candida.” Bulletin of biology and medicine problems 2.144 (2018): 83–6.

Sardi, J., Scorzoni, L., Bernardi, T., et al. “Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options.” Journal of medical microbiology 62.1 (2013): 10–24.

Nett, J., Lincoln, L., Marchillo, K., et al. “Putative role of β-1, 3 glucans in Candida albicans biofilm resistance.” Antimicrobial agents and chemotherapy 51.2 (2007): 510–20.

Dikke, G.B. “Pelvic floor muscle insufficiency and violation of the vaginal microbiocenosis: results of complex treatment.” Obstetrics and Gynecology 4 (2019). DOI: 10.18565/aig.2019.4

Kozlova, N.G., Dolgaya, I.N., Zamaraeva, E.E., et al. “Research in the field of creating suppository bases and a new nomenclature of suppositories of different directions of action.” Farmakom 2–3 (1994): 15–21.

Cagayan, S., Bravo, S.R., Fallarme, A.F. “Randomized, single-blinded comparison of efficacy, safety and tolerability of metronidazole 750 mg-miconazole 200 mg vaginal suppository vs. metronidazole 500 mg – nystatin 100,000 IU vaginal suppository in the treatment of bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis, and mixed vaginal infections.” PJOG 39.3 (2015).

Borovikov, I.O., Kutsenko, I.I., Rubinina, E.R. “Preconceptional preparation of patients with mixed vaginal dysbiosis.” RMJ. Mother and child 2.2 (2019). DOI: 10.32364/2618-8430-2019-2-2-113-119

McClelland, R.S, Balkus, J., Lee, J., et al. “Randomized Trial of Periodic Presumptive Treatment with High-Dose Intravaginal Metronidazole and Miconazole to Prevent Vaginal Infections in HIV-negative Women.” Journal of Infectious Diseases 211.12 (2015): 1875–82. DOI: 10.1093/infdis/jiu818

Bitsadze, V.O., Radetskaya, L.S. “The experience of using a local combined preparation containing metronidazole and miconazole for the treatment of bacterial vaginosis and candidal vulvovaginitis in pregnant women.” Gynecology 18.6 (2016): 56–60.

Ozyurt, E., Toykuliyeva, M.B., Danilyans, I.L. “Efficacy of 7-day treatment with metronidazolemiconazole Neo-Penotran a triple-active pessary for the treatment of single and mixed vaginal infections.” International Journal of Gynecology & Obstetrics 74 (2001): 35–43.

Weese, J.S., Walker, M., Lowe, T. “In vitro miconazole susceptibility of meticillin-resistant Staphylococcus pseudintermedius and Staphylococcus aureus.” Vet Dermatol 23 (2012): 400–2. DOI: 10.1111/j.1365- 3164.2012.01068.x

McClelland, R.S., Richardson, B.A., Hassan, W.M., et al. “Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial.” J Infect Dis 197 (2008): 1361–8.

Demkin, V.V. “Species diversity of lactobacilli of the vaginal microbiome: how to look.” Molekulyarnaya genetika, mikrobiologiya i virusologiya 36.3 (2018): 3–12. DOI: 10.17116/molgen2018360313

Borgdorff, H., Armstrong, S.D., Tytgat, H.L., et al. “Unique insights in the cervicovaginal Lactobacillus iners and L. crispatus Proteomes and their associations with microbiota dysbiosis.” PLoS ONE 11 (2016): e0150767. DOI: 10.1371/journal.pone.0150767

The Faculty of Sexual & Reproductive Healthcare of the Royal College of Obstetrician & Gynaecologists. Advice for women seeking contraception, abortion and other sexual and reproductive healthcare during the COVID-19 epidemic (2020). Available from: [https://www.fsrh.org/documents/advice-for-women-seeking-contraception-abortion-and-other], last accessed Jun 22, 2020.


GOST Style Citations


1.            Sherrard, J., Wilson, J., Donders, G., et al. “European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge.” International Journal of STD & AIDS 29.13 (2018): 1258–72.

2.            Калугина, Л.В, Татарчук Т. Ф., Шакало И. Н., и соавт. Неспецифический вульвовагинит смешанной этиологии: местное лечение – терапия выбора / Л.В. Калугина, Т.Ф. Татарчук, И.Н. Шакало и др. // Репродуктивна ендокринологія. – 2016. – № 1 (27). –С. 94–100.

3.            Frobenius, W., Bogdan, C. “Diagnostic Value of Vaginal Discharge, Wet Mount and Vaginal pH – An Update on the Basics of Gynecologic Infectiology.” Geburtshilfe Frauenheilkd 75.4 (2015): 355–66.

4.            Curry, A., Williams, T., Penny, M.L. “Pelvic Inflammatory Disease: Diagnosis, Management, and Prevention.” Am Fam Physician 100 (2019): 357–64.

5.            Бурка, О.А. Сучасні підходи до вибору антибактеріальних препаратів при запальних процесах тазових органів: роль інноваційних мікробіологічних методів / О.А. Бурка, Т.М. Тутченко, Н.Ю. Педаченко та ін. // Репродуктивна ендокринологія. – 2020. – № 1 (51). – С. 25–31.

6.            Tai, F.-W., Chang, C., Chiang, J.-H., et al. “Association of Pelvic Inflammatory Disease with Risk ofEndometriosis: A Nationwide Cohort Study Involving 141,460 Individuals.” J Clin Med 7 (2018): 379. DOI: 10.3390/jcm7110379

7.            Stewart, L.M., Stewart, C.J.R., Spilsbury, K., et al. “Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma.” Gynecol Oncol (2020). DOI:10.1016/j. ygyno.2020.01.027

8.            Brotman, R.M., Klebanoff, M.A., Tonia, R., et al. “Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection.” J Infect Dis 202 (2010): 1907–15.

9.            Rathod, S.D., Krupp, K., Klausner, J.D., et al. “Bacterial vaginosis and risk for Trichomonas vaginalis infection: a longitudinal analysis.” Sex Transm Dis 38 (2011): 882–6.

10.          Haggerty, C.L., Totten, P.A., Tang, G., et al. “Identification of novel microbes associated with pelvic inflammatory disease and infertility.” Sex Transm Infect 92 (2016): 441–6.

11.          Workowski, K.A., Bolan, G.A. “Sexually Transmitted Diseases Treatment Guidelines.” MMWR Recomm Rep 64 (RR 03) (2015): 1–137.

12.          Кузнецова, И. В. Диагностика и терапия смешанных и рецидивирующих вульвовагинальных инфекций / И.В. Кузнецова // Медицинский алфавит. – 2019. – № 25, Т. 3. Современная гинекология. – C. 23–29.

13.          Patterson, J.L., Girerd, P.H., Karjane, N.W., Jefferson, K.K. “Effect of biofilm phenotype on resistance of Gardnerella vaginalis to hydrogen peroxide and lactic acid.” Am J Obstet Gynecol 197 (2007): 170.

14.          Гусак, Ю.К., Рищук С.В., Тарасов В.Н. и соавт. Инфекционные заболевания влагалища. Поиски оптимального решения в их терапии. Защита или нападение? / Ю.К. Гусак, С.В. Рищук, В.Н. Тарасов и др. // Вестник новых медицинских технологий. Электронное издание. – 2019. – № 4. – C. 22–40.

15.          Mason, M.J., Winter, A.J. “How to diagnose and treatbaerobic and desquamative inflammatory vaginitis.” Sex Transm Infect 93 (2017): 8–10.

16.          Brotman, R.M., Klebanoff, M.A., Nansel, T.R., et al. “A longitudinal study of vaginal douching and bacterial vaginosis – a marginal structural modeling analysis.” Am J Epidemiol 168 (2008): 188–96.

17.          Bradshaw, C.S., Vodstrcil, L.A., Hocking, J.S., et al. “Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use.” Clin Infect Dis 56 (2013): 777–86.

18.          Neut, C., Verrière, F., Nelis, H.J., Coenye, T. “Topical Treatment of Infectious Vaginitis: Effects of Antibiotic, Antifungal and Antiseptic Drugs on the Growth of Normal Vaginal Lactobacillus Strains.” Open Journal of Obstetrics and Gynecology 5 (2015): 173–180. DOI: 10.4236/ojog.2015.53024

19.          McMillan, A., Dell, M., Zellar, M.P., et al. “Disruption of urogenital biofilms by lactobacilli.” Colloids Surf B Biointerfaces 86 (2011): 58–64. DOI: 10.1016/j. colsurfb.2011.03.016

20.          Юнгін, О.С. Антифунгальні агенти у розрізі набутої резистентності у грибів роду Сandida / О.С. Юнгін // Вісник проблем біології і медицини. – 2018. – Вип. 2, № 144. – С. 83–86.

21.          Sardi, J., Scorzoni, L., Bernardi, T., et al. “Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options.” Journal of medical microbiology 62.1 (2013): 10–24.

22.          Nett, J., Lincoln, L., Marchillo, K., et al. “Putative role of β-1, 3 glucans in Candida albicans biofilm resistance.” Antimicrobial agents and chemotherapy 51.2 (2007): 510–20.

23.          Дикке, Г.Б. Недостаточность мышц тазового дна и нарушение микробиоценоза влагалища: результаты комплексного лечения / Г.Б. Дикке // Акушерство и гинекология. – 2019. – №4.

24.          Козлова, Н.Г. Исследования в области создания суппозиторных основ и новой номенклатуры суппозиториев разной направленности действия / Н.Г. Козлова, И.Н. Долгая, Е.Е. Замараева и др. // Фармаком. – 1994. – № 2–3. – С.15–21.

25.          Cagayan, S., Bravo, S.R., Fallarme, A.F. “Randomized, single-blinded comparison of efficacy, safety and tolerability of metronidazole 750 mg-miconazole 200 mg vaginal suppository vs. metronidazole 500 mg – nystatin 100,000 IU vaginal suppository in the treatment of bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis, and mixed vaginal infections.” PJOG 39.3 (2015).

26.          Боровиков, И.О. Преконцепционная подготовка пациенток со смешанным вагинальным дисбиозом / И.О. Боровиков, И.И. Куценко, Э.Р. Рубинина // РМЖ. Мать и дитя. – 2019. – T.2, № 2.

27.          McClelland, R.S, Balkus, J., Lee, J., et al. “Randomized Trial of Periodic Presumptive Treatment with High-Dose Intravaginal Metronidazole and Miconazole to Prevent Vaginal Infections in HIV-negative Women.” Journal of Infectious Diseases 211.12 (2015): 1875–82. DOI: 10.1093/infdis/jiu818

28.          Бицадзе, В.О. Опыт применения местного комбинированного препарата, содержащего метронидазол и миконазол, для лечения бактериального вагиноза и кандидозного вульвовагинита у беременных / В.О. Бицадзе, Л.С. Радецкая // Гинекология 2016. – Т. 18, № 6. – C. 56–60.

29.          Ozyurt, E., Toykuliyeva, M.B., Danilyans, I.L. “Efficacy of 7-day treatment with metronidazolemiconazole Neo-Penotran a triple-active pessary for the treatment of single and mixed vaginal infections.” International Journal of Gynecology & Obstetrics 74 (2001): 35–43.

30.          Weese, J.S., Walker, M., Lowe, T. “In vitro miconazole susceptibility of meticillin-resistant Staphylococcus pseudintermedius and Staphylococcus aureus.” Vet Dermatol 23 (2012): 400–2. DOI: 10.1111/j.1365- 3164.2012.01068.x

31.          McClelland, R.S., Richardson, B.A., Hassan, W.M., et al. “Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial.” J Infect Dis 197 (2008): 1361–8.

32.          Demkin, V.V. “Species diversity of lactobacilli of the vaginal microbiome: how to look.” Molekulyarnaya genetika, mikrobiologiya i virusologiya 36.3 (2018): 3–12. DOI: 10.17116/molgen2018360313

33. Borgdorff, H., Armstrong, S.D., Tytgat, H.L., et al. “Unique insights in the cervicovaginal Lactobacillus iners and L. crispatus Proteomes and their associations with microbiota dysbiosis.” PLoS ONE 11 (2016): e0150767. DOI: 10.1371/journal.pone.0150767

34. The Faculty of Sexual & Reproductive Healthcare of the Royal College of Obstetrician & Gynaecologists. Advice for women seeking contraception, abortion and other sexual and reproductive healthcare during the COVID-19 epidemic (2020). Available from: [https://www.fsrh.org/documents/advice-for-women-seeking-contraception-abortion-and-other], last accessed Jun 22, 2020.





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)